PF-08634404

DRUG17 trials

Sponsors

Pfizer Inc., Pfizer

Conditions

ADVANCED OR METASTATIC RENAL CELL CARCINOMAAdvanced Hepatocellular CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced Renal Cell CarcinomaAdvanced Solid TumorsAdvanced or Metastatic Renal Cell CarcinomaAdvanced/Metastatic Non-Small Cell Lung CancerAdvanced/Metastatic Urothelial Cancer

Phase 1

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

RecruitingNCT07227012

PfizerAdvanced Hepatocellular Carcinoma, Carcinoma, Hepatocellular, Hepatocellular Cancer +4

Start: 2025-12-01End: 2028-10-17Target: 138Updated: 2026-04-20

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

RecruitingNCT07227298

PfizerAdvanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer

Start: 2026-01-30End: 2033-08-23Target: 162Updated: 2026-04-20

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

RecruitingNCT07227415

PfizerAdvanced or Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Renal Cell +10

Start: 2026-02-10End: 2028-11-01Target: 224Updated: 2026-05-22

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

RecruitingNCT07421700

PfizerAdvanced/Metastatic Urothelial Cancer, Urothelial Cancer, Urothelial Carcinoma

Start: 2026-03-11End: 2028-09-05Target: 132Updated: 2026-04-20

C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

Not yet recruitingCTIS2025-523525-17-00

Pfizer Inc.Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

Target: 68Updated: 2026-04-10

C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors

Not yet recruitingCTIS2025-523526-40-00

Pfizer Inc.Advanced Solid Tumors

Target: 43Updated: 2026-04-10

C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Not yet recruitingCTIS2025-523524-53-00

Pfizer Inc.ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Target: 50Updated: 2026-04-22

Phase 2

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

RecruitingNCT07226999

PfizerSmall Cell Lung Cancer (SCLC)

Start: 2025-12-09End: 2034-03-11Target: 550Updated: 2026-04-20

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

RecruitingNCT07392892

PfizerEsophageal Adenocarcinoma, Gastroesophageal Junction Cancer, Metastatic Gastric Cancer +1

Start: 2026-04-28End: 2032-07-21Target: 840Updated: 2026-04-13

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

RecruitingNCT07476287

PfizerCarcinoma, Small Cell Lung, Lung Neoplasms, Small Cell Cancer Of The Lung +3

Start: 2026-05-15End: 2031-03-19Target: 40Updated: 2026-04-20

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Not yet recruitingNCT07489066

PfizerCarcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer (NSCLC) +6

Start: 2026-04-01End: 2031-08-05Target: 120Updated: 2026-03-23

C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Not yet recruitingCTIS2025-523522-41-00

Pfizer Inc.Extensive-Stage Small Cell Lung Cancer

Target: 47Updated: 2026-04-07

Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

RecruitingNCT07222566

PfizerAdvanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) +3

Start: 2026-01-06End: 2032-08-26Target: 1410Updated: 2026-05-20

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

RecruitingNCT07222800

PfizerColonic Diseases, Colorectal Neoplasms, Digestive System Diseases +7

Start: 2025-12-11End: 2031-08-01Target: 800Updated: 2026-04-21

C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

Not yet recruitingCTIS2025-523521-18-00

Pfizer Inc.Metastatic Colorectal Cancer

Target: 20Updated: 2026-03-23

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Not yet recruitingCTIS2025-523461-17-01

Pfizer Inc.LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Target: 203Updated: 2026-03-25

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

Not yet recruitingNCT07578649

PfizerEndometrial Cancer, Endometrial Neoplasms

Start: 2026-10-09End: 2031-01-30Target: 600Updated: 2026-05-19